Company Overview and News

 
CLSH / CLS Holdings USA, Inc. FORM 10-Q (Quarterly Report)

2018-10-12 sec.gov
cls20180831_10q.htm UNITED STATES
CLSH

 
CLSH / CLS Holdings USA, Inc. FORM 8-K (Current Report)

2018-10-09 sec.gov
cls20181005_8k.htm
CLSH

 
CLSH / CLS Holdings USA, Inc. FORM 8-K (Current Report)

2018-10-04 sec.gov
cls20181003_8k.htm UNITED STATES
CLSH

 
Cannabis Life Sciences Discusses the Benefits of Medical Marijuana with Uptick Newswire’s Stock Day Podcast and Addresses Its Potential Entry into The Massachusetts Market

2018-09-20 globenewswire
PHOENIX, Sept. 20, 2018 (GLOBE NEWSWIRE) -- CLS Holdings USA, Inc. (OTCQB: CLSH) (CLS Holdings, Inc.), also known as Cannabis Life Sciences, does not want to lose sight of how its product can ultimately help people as they expand their market share. Jeffrey Binder, Chairman and Chief Executive Officer of CLS, tells Stock Day’s Everett Jolly there are many opportunities on the horizon.
MJNA CLSH CLSH]

 
CLS Holdings USA Executes Two Letters of Intent, which will provide the Opportunity to Enter the Rapidly Expanding Massachusetts Market

2018-09-17 globenewswire
LAS VEGAS, Sept. 17, 2018 (GLOBE NEWSWIRE) -- CLS Holdings USA, Inc. (OTCQB: CLSH) “CLS,” a diversified cannabis company operating as Cannabis Life Sciences and an integrated cannabis producer and retailer in Nevada through its Oasis Cannabis subsidiaries, today announced it has executed two Letters of Intent (LOIs) to enter the rapidly growing Massachusetts market. CLS looks forward to the opportunity to enter the Massachusetts market, which has been operating as a legalized medical jurisdiction since 2015 and has approved legalized recreational use.
CLSH CLSH]

 
CLSH / CLS Holdings USA, Inc. FORM 8-K/A (Current Report)

2018-09-11 sec.gov
cls20180910_8ka.htm UNITED STATES
CLSH

 
CLSH / CLS Holdings USA, Inc. FORM 10-K (Annual Report)

2018-08-29 sec.gov
cls20180531_10k.htm UNITED STATES
CLSH

 
CLSH / CLS Holdings USA, Inc. FORM S-1

2018-08-29 sec.gov
cls20180827_s1.htm As filed with the Securities and Exchange Commission on August 28, 2018
CLSH

 
CLSH / CLS Holdings USA, Inc. FORM S-1

2018-08-29 sec.gov
cls20180827_s1.htm As filed with the Securities and Exchange Commission on August 28, 2018
CLSH

 
CLS Holdings USA Names Matthew Janz as VP of Marketing and Director of Operations at Oasis Cannabis

2018-08-21 globenewswire
LAS VEGAS, Aug. 21, 2018 (GLOBE NEWSWIRE) -- CLS Holdings USA, Inc. (OTCQB: CLSH) “CLS,” a diversified cannabis company operating as Cannabis Life Sciences and an integrated cannabis producer and retailer in Nevada through its Oasis Cannabis subsidiary, today announced that Matthew Janz has joined the Company as VP of Marketing and Director of Operations at Oasis Cannabis.
CLSH CLSH]

 
CLSH / CLS Holdings USA, Inc. FORM 8-K (Current Report)

2018-08-13 sec.gov
cls20180813_8k.htm
CLSH

 
CLSH / CLS Holdings USA, Inc. FORM 8-K (Current Report)

2018-08-08 sec.gov
cls20180807_8k.htm UNITED STATES
CLSH

 
CLS Holdings USA Closes $3 Million Investment from Navy Capital

2018-08-07 globenewswire
LAS VEGAS, Aug. 07, 2018 (GLOBE NEWSWIRE) -- CLS Holdings USA, Inc. (OTCQB: CLSH) “CLS,” a diversified cannabis company operating as Cannabis Life Sciences and an integrated cannabis producer and retailer in Nevada through its Oasis Cannabis subsidiary, today announced the closing of a $3 million equity investment from Navy Capital Green International, Ltd., a cannabis-focused institutional fund based in New York City.
CLSH CLSH]

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...